Second-trimester abortion by intramuscular 15-methyl-prostaglandin F2α or intravaginal prostaglandin E2 suppositories: A randomized trial

Obstetrics and Gynecology

Volumn 85, Issue 5, 1995, Pages 697-700

  Borgida, Adam F ^a   Rodis, John F ^a   Hanlon, Wendy ^a   Craffey, Alicia ^a   Ciarleglio, Leslie ^a   Campbell, Winston A ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPROST; PROSTAGLANDIN E2;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INDUCED ABORTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABORTION, INDUCED; ADULT; CARBOPROST; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PROSTAGLANDINS E; SUPPOSITORIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0028967842     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(95)00011-F     Document Type: Article

References (12)

1. Centers for Disease Control
2. Surgical abortion
3. 2 suppositories as a second-trimester abortifacient
4. 2α
5. 2 for termination of second-trimester pregnancy
6. 2α for midtrimester abortion
7. 2α
8. Clinicians who provide abortion: The thinning ranks
9. 2α and termination of middle and late second-trimester pregnancy for genetic indications: A contemporary approach
10. 2α in fetal death, missed, and therapeutic abortions
11. 2α administration for mid-trimester pregnancy termination: A case report